骨性蛋白与帕金森病的研究进展  

Research progress of bone protein and Parkinson’s disease

作　　者：刘娜[1] 钱小娟 张杨 蒋森 雍雨暄 杨新玲[1] LIU Na;QIAN Xiaojuan;ZHANG Yang;JIANG Sen;YONG Yuxuan;YANG Xinling(The Second Affiliated Hospital of Xinjiang Medical University,Urumqi 830000,China)

机构地区：[1]新疆医科大学第二附属医院,新疆乌鲁木齐830000

出　　处：《中国实用神经疾病杂志》2021年第13期1181-1185,共5页Chinese Journal of Practical Nervous Diseases

基　　金：新疆自治区科技支疆项目(编号:2019E0280)。

摘　　要：帕金森病(Pankinson’s disease,PD)是一种老年性退行性疾病,临床诊断较为困难。疾病晚期阶段可使患者生活质量显著下降。研究表明,PD患者不仅骨的钙磷代谢失衡,导致骨密度下降,同时一些骨细胞分泌的骨性蛋白,如骨桥蛋白、骨钙素以及骨保护素也可能参与PD的发生发展,这一发现为PD的诊断、治疗提供新思路。本文将从骨桥蛋白、骨钙素及骨保护素参与PD的发病机制与认知功能的关系以及神经保护机制等方面进行阐述。Parkinson’s disease is a senile degenerative disease,clinical diagnosis is difficult.The advanced stage of disease can significantly reduce the quality of life of patients.Some studies have shown that PD patients will not only affect bone calcium and phosphorus metabolism imbalance,resulting in a decrease in bone mineral density,while some bone proteins secreted by bone cells such as osteopontin,osteocalcin and osteoprotegerin may also participate in the development of PD.This finding provides a new idea for the diagnosis and treatment of PD.A review is made of the role of osteopontin,osteocalcin and osteoprotegerin in PD pathogenesis,relationship with cognitive function and neuroprotective effects.

关 键 词：帕金森病 骨桥蛋白 骨钙素 骨保护素 

分 类 号：R742.5[医药卫生—神经病学与精神病学]